3nga › Citations

Structural basis of CX-4945 binding to human protein kinase CK2.

Ferguson AD, Sheth PR, Basso AD, Paliwal S, Gray K, Fischmann TO, Le HV
FEBS Lett 585 104-10 (2011)
Cited: 73 times
EuropePMC logo PMID: 21093442

Abstract

Protein kinase CK2 (CK2), a constitutively active serine/threonine kinase, is involved in a variety of roles essential to the maintenance of cellular homeostasis. Elevated levels of CK2 expression results in the dysregulation of key signaling pathways that regulate transcription, and has been implicated in cancer. The adenosine-5'-triphosphate-competitive inhibitor CX-4945 has been reported to show broad spectrum anti-proliferative activity in multiple cancer cell lines. Although the enzymatic IC(50) of CX-4945 has been reported, the thermodynamics and structural basis of binding to CK2α remained elusive. Presented here are the crystal structures of human CK2α in complex with CX-4945 and adenylyl phosphoramidate at 2.7 and 1.3 Å, respectively. Biophysical analysis of CX-4945 binding is also described. This data provides the structural rationale for the design of more potent inhibitors against this emerging cancer target.

Reviews - 3nga mentioned but not cited (2)

  1. The Development of CK2 Inhibitors: From Traditional Pharmacology to in Silico Rational Drug Design. Cozza G. Pharmaceuticals (Basel) 10 (2017)
  2. Downfalls of Chemical Probes Acting at the Kinase ATP-Site: CK2 as a Case Study. Atkinson EL, Iegre J, Brear PD, Zhabina EA, Hyvönen M, Spring DR. Molecules 26 1977 (2021)

Articles - 3nga mentioned but not cited (8)

  1. Specific inhibition of CK2α from an anchor outside the active site. Brear P, De Fusco C, Hadje Georgiou K, Francis-Newton NJ, Stubbs CJ, Sore HF, Venkitaraman AR, Abell C, Spring DR, Hyvönen M. Chem Sci 7 6839-6845 (2016)
  2. 2-Aminothiazole Derivatives as Selective Allosteric Modulators of the Protein Kinase CK2. 1. Identification of an Allosteric Binding Site. Bestgen B, Krimm I, Kufareva I, Kamal AAM, Seetoh WG, Abell C, Hartmann RW, Abagyan R, Cochet C, Le Borgne M, Engel M, Lomberget T. J Med Chem 62 1803-1816 (2019)
  3. Isomeric mono-, di-, and tri-bromobenzo-1H-triazoles as inhibitors of human protein kinase CK2α. Wąsik R, Wińska P, Poznański J, Shugar D. PLoS ONE 7 e48898 (2012)
  4. Structural determinants of CX-4945 derivatives as protein kinase CK2 inhibitors: a computational study. Liu H, Wang X, Wang J, Wang J, Li Y, Yang L, Li G. Int J Mol Sci 12 7004-7021 (2011)
  5. The crystal structure of the protein kinase HIPK2 reveals a unique architecture of its CMGC-insert region. Agnew C, Liu L, Liu S, Xu W, You L, Yeung W, Kannan N, Jablons D, Jura N. J. Biol. Chem. 294 13545-13559 (2019)
  6. Diacritic Binding of an Indenoindole Inhibitor by CK2α Paralogs Explored by a Reliable Path to Atomic Resolution CK2α' Structures. Lindenblatt D, Nickelsen A, Applegate VM, Hochscherf J, Witulski B, Bouaziz Z, Marminon C, Bretner M, Le Borgne M, Jose J, Niefind K. ACS Omega 4 5471-5478 (2019)
  7. Discovery of a Potent and Selective Naphthyridine-Based Chemical Probe for Casein Kinase 2. Davis-Gilbert ZW, Krämer A, Dunford JE, Howell S, Senbabaoglu F, Wells CI, Bashore FM, Havener TM, Smith JL, Hossain MA, Oppermann U, Drewry DH, Axtman AD. ACS Med Chem Lett 14 432-441 (2023)
  8. Structural analysis of fungal pathogenicity-related casein kinase α subunit, Cka1, in the human fungal pathogen Cryptococcus neoformans. Ong BX, Yoo Y, Han MG, Park JB, Choi MK, Choi Y, Shin JS, Bahn YS, Cho HS. Sci Rep 9 14398 (2019)


Reviews citing this publication (7)

  1. Protein kinase CK2 inhibitors: a patent review. Cozza G, Pinna LA, Moro S. Expert Opin Ther Pat 22 1081-1097 (2012)
  2. Structural and functional determinants of protein kinase CK2α: facts and open questions. Battistutta R, Lolli G. Mol. Cell. Biochem. 356 67-73 (2011)
  3. ATP Analogues for Structural Investigations: Case Studies of a DnaB Helicase and an ABC Transporter. Lacabanne D, Wiegand T, Wili N, Kozlova MI, Cadalbert R, Klose D, Mulkidjanian AY, Meier BH, Böckmann A. Molecules 25 E5268 (2020)
  4. Role of CK2 inhibitor CX-4945 in anti-cancer combination therapy - potential clinical relevance. D'Amore C, Borgo C, Sarno S, Salvi M. Cell Oncol (Dordr) 43 1003-1016 (2020)
  5. The Role of Protein Kinase CK2 in Development and Disease Progression: A Critical Review. Halloran D, Pandit V, Nohe A. J Dev Biol 10 31 (2022)
  6. Function of protein kinase CK2 in thrombus formation. Ampofo E, Schmitt BM, Laschke MW, Menger MD. Platelets 30 421-427 (2019)
  7. [Protein kinase CK2 and human malignant tumors]. Huang Y, Zhou S, Xue H, Zhao Z, Wang L. Zhongguo Fei Ai Za Zhi 15 439-445 (2012)

Articles citing this publication (56)

  1. Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer. Pierre F, Chua PC, O'Brien SE, Siddiqui-Jain A, Bourbon P, Haddach M, Michaux J, Nagasawa J, Schwaebe MK, Stefan E, Vialettes A, Whitten JP, Chen TK, Darjania L, Stansfield R, Bliesath J, Drygin D, Ho C, Omori M, Proffitt C, Streiner N, Rice WG, Ryckman DM, Anderes K. Mol. Cell. Biochem. 356 37-43 (2011)
  2. Unprecedented selectivity and structural determinants of a new class of protein kinase CK2 inhibitors in clinical trials for the treatment of cancer. Battistutta R, Cozza G, Pierre F, Papinutto E, Lolli G, Sarno S, O'Brien SE, Siddiqui-Jain A, Haddach M, Anderes K, Ryckman DM, Meggio F, Pinna LA. Biochemistry 50 8478-8488 (2011)
  3. Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutations. Littlefield P, Liu L, Mysore V, Shan Y, Shaw DE, Jura N. Sci Signal 7 ra114 (2014)
  4. The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies. Chon HJ, Bae KJ, Lee Y, Kim J. Front Pharmacol 6 70 (2015)
  5. Druggability of the CK2 inhibitor CX-4945 as an anticancer drug and beyond. Kim J, Kim SH. Arch. Pharm. Res. 35 1293-1296 (2012)
  6. Identification of a novel function of CX-4945 as a splicing regulator. Kim H, Choi K, Kang H, Lee SY, Chi SW, Lee MS, Song J, Im D, Choi Y, Cho S. PLoS ONE 9 e94978 (2014)
  7. A chemical with proven clinical safety rescues Down-syndrome-related phenotypes in through DYRK1A inhibition. Kim H, Lee KS, Kim AK, Choi M, Choi K, Kang M, Chi SW, Lee MS, Lee JS, Lee SY, Song WJ, Yu K, Cho S. Dis Model Mech 9 839-848 (2016)
  8. Enzymatic activity with an incomplete catalytic spine: insights from a comparative structural analysis of human CK2α and its paralogous isoform CK2α'. Bischoff N, Raaf J, Olsen B, Bretner M, Issinger OG, Niefind K. Mol. Cell. Biochem. 356 57-65 (2011)
  9. Discovery and the structural basis of a novel p21-activated kinase 4 inhibitor. Ryu BJ, Kim S, Min B, Kim KY, Lee JS, Park WJ, Lee H, Kim SH, Park S. Cancer Lett. 349 45-50 (2014)
  10. Low-density crystal packing of human protein kinase CK2 catalytic subunit in complex with resorufin or other ligands: a tool to study the unique hinge-region plasticity of the enzyme without packing bias. Klopffleisch K, Issinger OG, Niefind K. Acta Crystallogr. D Biol. Crystallogr. 68 883-892 (2012)
  11. Enzyme Activities of the Ceramide Synthases CERS2-6 Are Regulated by Phosphorylation in the C-terminal Region. Sassa T, Hirayama T, Kihara A. J. Biol. Chem. 291 7477-7487 (2016)
  12. PML Degradation: Multiple Ways to Eliminate PML. Rabellino A, Scaglioni PP. Front Oncol 3 60 (2013)
  13. Structural and functional analysis of the flexible regions of the catalytic α-subunit of protein kinase CK2. Papinutto E, Ranchio A, Lolli G, Pinna LA, Battistutta R. J. Struct. Biol. 177 382-391 (2012)
  14. Structure-based discovery of novel flavonol inhibitors of human protein kinase CK2. Golub AG, Bdzhola VG, Kyshenia YV, Sapelkin VM, Prykhod'ko AO, Kukharenko OP, Ostrynska OV, Yarmoluk SM. Mol. Cell. Biochem. 356 107-115 (2011)
  15. A suite of Switch I and Switch II mutant structures from the G-protein domain of FeoB. Ash MR, Maher MJ, Guss JM, Jormakka M. Acta Crystallogr. D Biol. Crystallogr. 67 973-980 (2011)
  16. Exploring the prominent performance of CX-4945 derivatives as protein kinase CK2 inhibitors by a combined computational study. Wang X, Pan P, Li Y, Li D, Hou T. Mol Biosyst 10 1196-1210 (2014)
  17. CIGB-300, an anti-CK2 peptide, inhibits angiogenesis, tumor cell invasion and metastasis in lung cancer models. Benavent Acero F, Capobianco CS, Garona J, Cirigliano SM, Perera Y, Urtreger AJ, Perea SE, Alonso DF, Farina HG. Lung Cancer 107 14-21 (2017)
  18. Functional proteomics strategy for validation of protein kinase inhibitors reveals new targets for a TBB-derived inhibitor of protein kinase CK2. Gyenis L, Kuś A, Bretner M, Litchfield DW. J Proteomics 81 70-79 (2013)
  19. Halogen bonding at the ATP binding site of protein kinases: preferred geometry and topology of ligand binding. Poznański J, Shugar D. Biochim. Biophys. Acta 1834 1381-1386 (2013)
  20. Structural basis for low-affinity binding of non-R2 carboxylate-substituted tricyclic quinoline analogs to CK2α: comparative molecular dynamics simulation studies. Zhou Y, Li X, Zhang N, Zhong R. Chem Biol Drug Des 85 189-200 (2015)
  21. TET1 reprograms the epithelial ovarian cancer epigenome and reveals casein kinase 2α as a therapeutic target. Chen LY, Huang RL, Chan MW, Chan MW, Yan PS, Huang TS, Wu RC, Suryo Rahmanto Y, Su PH, Weng YC, Chou JL, Chao TK, Wang YC, Shih IM, Lai HC. J Pathol 248 363-376 (2019)
  22. Biochemical analysis of TOPBP1 oligomerization. Kim A, Montales K, Ruis K, Senebandith H, Gasparyan H, Cowan Q, Michael WM. DNA Repair (Amst) 96 102973 (2020)
  23. Biochemical and Structural Insights into Doublecortin-like Kinase Domain 1. Patel O, Dai W, Mentzel M, Griffin MD, Serindoux J, Gay Y, Fischer S, Sterle S, Kropp A, Burns CJ, Ernst M, Buchert M, Lucet IS. Structure 24 1550-1561 (2016)
  24. Casein Kinase 2: a novel player in glioblastoma therapy and cancer stem cells. Agarwal M, Nitta RT, Li G. J Mol Genet Med 8 (2013)
  25. Halogen Atoms in the Protein-Ligand System. Structural and Thermodynamic Studies of the Binding of Bromobenzotriazoles by the Catalytic Subunit of Human Protein Kinase CK2. Czapinska H, Winiewska-Szajewska M, Szymaniec-Rutkowska A, Piasecka A, Bochtler M, Poznański J. J Phys Chem B 125 2491-2503 (2021)
  26. Identification of novel CK2 inhibitors with a benzofuran scaffold by novel non-radiometric in vitro assays. Gratz A, Kuckländer U, Bollig R, Götz C, Jose J. Mol Cell Biochem 356 83-90 (2011)
  27. Structural Hypervariability of the Two Human Protein Kinase CK2 Catalytic Subunit Paralogs Revealed by Complex Structures with a Flavonol- and a Thieno[2,3-d]pyrimidine-Based Inhibitor. Niefind K, Bischoff N, Golub AG, Bdzhola VG, Balanda AO, Prykhod'ko AO, Yarmoluk SM. Pharmaceuticals (Basel) 10 (2017)
  28. 2-Aminothiazole Derivatives as Selective Allosteric Modulators of the Protein Kinase CK2. 2. Structure-Based Optimization and Investigation of Effects Specific to the Allosteric Mode of Action. Bestgen B, Kufareva I, Seetoh W, Abell C, Hartmann RW, Abagyan R, Le Borgne M, Filhol O, Cochet C, Lomberget T, Engel M. J Med Chem 62 1817-1836 (2019)
  29. Identification of Bacillus anthracis PurE inhibitors with antimicrobial activity. Kim A, Wolf NM, Zhu T, Johnson ME, Deng J, Cook JL, Fung LW. Bioorg. Med. Chem. 23 1492-1499 (2015)
  30. Inhibition of casein kinase 2 prevents growth of human osteosarcoma. Takahashi K, Setoguchi T, Tsuru A, Saitoh Y, Nagano S, Ishidou Y, Maeda S, Furukawa T, Komiya S. Oncol. Rep. 37 1141-1147 (2017)
  31. Simultaneous CK2/TNIK/DYRK1 inhibition by 108600 suppresses triple negative breast cancer stem cells and chemotherapy-resistant disease. Sato K, Padgaonkar AA, Baker SJ, Cosenza SC, Rechkoblit O, Subbaiah DRCV, Domingo-Domenech J, Bartkowski A, Port ER, Aggarwal AK, Ramana Reddy MV, Irie HY, Reddy EP. Nat Commun 12 4671 (2021)
  32. A novel allosteric site in casein kinase 2α discovered using combining bioinformatics and biochemistry methods. Jiang HM, Dong JK, Song K, Wang TD, Huang WK, Zhang JM, Yang XY, Shen Y, Zhang J. Acta Pharmacol. Sin. 38 1691-1698 (2017)
  33. Elevating CDCA3 levels in non-small cell lung cancer enhances sensitivity to platinum-based chemotherapy. Kildey K, Gandhi NS, Sahin KB, Shah ET, Boittier E, Duijf PHG, Molloy C, Burgess JT, Beard S, Bolderson E, Suraweera A, Richard DJ, O'Byrne KJ, Adams MN. Commun Biol 4 638 (2021)
  34. Inactivation of paracellular cation-selective claudin-2 channels attenuates immune-mediated experimental colitis in mice. Raju P, Shashikanth N, Tsai PY, Pongkorpsakol P, Chanez-Paredes S, Steinhagen PR, Kuo WT, Singh G, Tsukita S, Turner JR. J Clin Invest 130 5197-5208 (2020)
  35. Proposed Allosteric Inhibitors Bind to the ATP Site of CK2α. Brear P, Ball D, Stott K, D'Arcy S, Hyvönen M. J Med Chem 63 12786-12798 (2020)
  36. Sexually dimorphic DYRK1A overexpression on postnatal day 15 in the Ts65Dn mouse model of Down syndrome: Effects of pharmacological targeting on behavioral phenotypes. Hawley LE, Prochaska F, Stringer M, Goodlett CR, Roper RJ. Pharmacol Biochem Behav 217 173404 (2022)
  37. Activation of RyR2 by class I kinase inhibitors. Chakraborty AD, Gonano LA, Munro ML, Smith LJ, Thekkedam C, Staudacher V, Gamble AB, Macquaide N, Dulhunty AF, Jones PP. Br J Pharmacol 176 773-786 (2019)
  38. Bioactivity and Molecular Docking Studies of Derivatives from Cinnamic and Benzoic Acids. Perez-Castillo Y, Lima TC, Ferreira AR, Silva CR, Campos RS, Neto JBA, Magalhães HIF, Cavalcanti BC, Júnior HVN, de Sousa DP. Biomed Res Int 2020 6345429 (2020)
  39. ITC-derived binding affinity may be biased due to titrant (nano)-aggregation. Binding of halogenated benzotriazoles to the catalytic domain of human protein kinase CK2. Winiewska M, Bugajska E, Poznański J. PLoS ONE 12 e0173260 (2017)
  40. Identification of protein kinase CK2 inhibitors using solvent dipole ordering virtual screening. Nakanishi I, Murata K, Nagata N, Kurono M, Kinoshita T, Yasue M, Miyazaki T, Takei Y, Nakamura S, Sakurai A, Iwamoto N, Nishiwaki K, Nakaniwa T, Sekiguchi Y, Hirasawa A, Tsujimoto G, Kitaura K. Eur J Med Chem 96 396-404 (2015)
  41. Impact of protein kinase CK2 inhibitors on proliferation and differentiation of neural stem cells. Bender M, Schwind L, Grundmann D, Martin M, Klotz M, Götz C, Montenarh M, Schäfer KH. Heliyon 3 e00318 (2017)
  42. Structure and Function of the Hypertension Variant A486V of G Protein-coupled Receptor Kinase 4. Allen SJ, Parthasarathy G, Darke PL, Diehl RE, Ford RE, Hall DL, Johnson SA, Reid JC, Rickert KW, Shipman JM, Soisson SM, Zuck P, Munshi SK, Lumb KJ. J. Biol. Chem. 290 20360-20373 (2015)
  43. Affinity characterization-mass spectrometry methodology for quantitative analyses of small molecule protein binding in solution. Vilenchik LZ, Sheth PR, Chuang CC, Le HV. Anal. Biochem. 418 10-18 (2011)
  44. Competition between electrostatic interactions and halogen bonding in the protein-ligand system: structural and thermodynamic studies of 5,6-dibromobenzotriazole-hCK2α complexes. Winiewska-Szajewska M, Czapinska H, Kaus-Drobek M, Fricke A, Mieczkowska K, Dadlez M, Bochtler M, Poznański J. Sci Rep 12 18964 (2022)
  45. Crystal structure of Arabidopsis thaliana casein kinase 2 α1. Demulder M, De Veylder L, Loris R. Acta Crystallogr F Struct Biol Commun 76 182-191 (2020)
  46. Crystal structures of human CK2α2 in new crystal forms arising from a subtle difference in salt concentration. Tsuyuguchi M, Nakaniwa T, Kinoshita T. Acta Crystallogr F Struct Biol Commun 74 288-293 (2018)
  47. Design, synthesis and biological evaluation of 2-aminopyrimidinones and their 6-aza-analogs as a new class of CK2 inhibitors. Chekanov MO, Ostrynska OV, Tarnavskyi SS, Synyugin AR, Briukhovetska NV, Bdzhola VG, Pashenko AE, Fokin AA, Yarmoluk SM. J Enzyme Inhib Med Chem 29 639-646 (2014)
  48. Dihydrobenzo[4,5]imidazo[1,2-a]pyrimidine-4-ones as a new class of CK2 inhibitors. Protopopov MV, Ostrynska OV, Starosyla SA, Vodolazhenko MA, Sirko SM, Gorobets NY, Bdzhola V, Desenko SM, Yarmoluk SM. Mol. Divers. 22 991-998 (2018)
  49. Metastable asymmetrical structure of a shaftless V1 motor. Maruyama S, Suzuki K, Imamura M, Sasaki H, Matsunami H, Mizutani K, Saito Y, Imai FL, Ishizuka-Katsura Y, Kimura-Someya T, Shirouzu M, Uchihashi T, Ando T, Yamato I, Murata T. Sci Adv 5 eaau8149 (2019)
  50. Non-catalytic allostery in α-TAT1 by a phospho-switch drives dynamic microtubule acetylation. Deb Roy A, Gross EG, Pillai GS, Seetharaman S, Etienne-Manneville S, Inoue T. J Cell Biol 221 e202202100 (2022)
  51. Silmitasertib (CX-4945), a Clinically Used CK2-Kinase Inhibitor with Additional Effects on GSK3β and DYRK1A Kinases: A Structural Perspective. Grygier P, Pustelny K, Nowak J, Golik P, Popowicz GM, Plettenburg O, Dubin G, Menezes F, Czarna A. J Med Chem 66 4009-4024 (2023)
  52. Structural analysis of PIM1 kinase complexes with ATP-competitive inhibitors. Bogusz J, Zrubek K, Rembacz KP, Grudnik P, Golik P, Romanowska M, Wladyka B, Dubin G. Sci Rep 7 13399 (2017)
  53. The Anti-Candida albicans Agent 4-AN Inhibits Multiple Protein Kinases. Masłyk M, Janeczko M, Martyna A, Czernik S, Tokarska-Rodak M, Chwedczuk M, Foll-Josselin B, Ruchaud S, Bach S, Demchuk OM, Kubiński K. Molecules 24 (2019)
  54. The multiple nucleotide-divalent cation binding modes of Saccharomyces cerevisiae CK2α indicate a possible co-substrate hydrolysis product (ADP/GDP) release pathway. Liu H, Wang H, Teng M, Li X. Acta Crystallogr. D Biol. Crystallogr. 70 501-513 (2014)
  55. The protein kinase CK2 catalytic domain from Plasmodium falciparum: crystal structure, tyrosine kinase activity and inhibition. Ruiz-Carrillo D, Lin J, El Sahili A, Wei M, Sze SK, Cheung PCF, Doerig C, Lescar J. Sci Rep 8 7365 (2018)
  56. Unexpected Binding Mode of a Potent Indeno[1,2-b]indole-Type Inhibitor of Protein Kinase CK2 Revealed by Complex Structures with the Catalytic Subunit CK2α and Its Paralog CK2α'. Hochscherf J, Lindenblatt D, Witulski B, Birus R, Aichele D, Marminon C, Bouaziz Z, Le Borgne M, Jose J, Niefind K. Pharmaceuticals (Basel) 10 (2017)


Quick links